AZ Looks To Lead Severe Asthma Market After US Fasenra OK
Executive Summary
Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.
You may also be interested in...
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.
Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.
AZ's Fasenra Hits First Hurdle Hard In COPD Study
AstraZeneca’s bid to expand its respiratory biologic Fasenra from asthma into the chronic obstructive pulmonary disease space has been hurt by a Phase III failure but the company is holding its horses until the results of another large late-stage trial come in before the end of this quarter.